HC Wainwright Brokers Reduce Earnings Estimates for ABEO

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at HC Wainwright decreased their Q2 2025 earnings estimates for shares of Abeona Therapeutics in a research note issued on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter, down from their prior forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.57 EPS.

A number of other equities research analysts have also recently commented on ABEO. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.56 on Friday. The stock has a fifty day moving average price of $5.09 and a 200 day moving average price of $5.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a market cap of $320.13 million, a PE ratio of -2.44 and a beta of 1.71. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Insider Activity at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares in the company, valued at $6,478,439.16. The trade was a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently bought and sold shares of ABEO. Twinbeech Capital LP purchased a new position in shares of Abeona Therapeutics during the 4th quarter worth $58,000. Squarepoint Ops LLC purchased a new position in Abeona Therapeutics during the fourth quarter worth about $67,000. Cannon Global Investment Management LLC acquired a new stake in Abeona Therapeutics in the 1st quarter worth about $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the 3rd quarter valued at about $84,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $118,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.